CEYESTO® Granted Expanded UK Indication By the MHRA

MEDICAL AND TRADE PRESS RELEASE: Issued Tuesday 22nd November 2022

Announced today, ALTURiX – a rapidly-growing British pharmaceutical company – has been granted an expanded indication in the UK for CEYESTO® 3mg Tablets, an immediate release form of melatonin.

CEYESTO® has been available in the UK for over a year for the short term treatment of jet lag in adults, and has now also been approved by the MHRA for Insomnia in children and adolescents aged 6-17 years with ADHD, where sleep hygiene measures have been insufficient.

Commenting on the approval, Lak Sahota, Founder and Director at ALTURiX said, 

“The treatment of insomnia in young patients with ADHD is complex.  We are delighted that we can help by increasing the number of licensed treatment options available to prescribers and patients. Melatonin prescribing costs continue to increase and potentially we are able to help the NHS save over £20m on its annual melatonin prescribing in this age group.  As part of our Medicines Value Programme, Ceyesto® is a product at the very heart of our approach at ALTURiX, offering value to the NHS at fair and appropriate prices.”  

Read more…

Latest articles